AbCellera Biologics Inc. (ABCL)
| Market Cap | 1.26B |
| Revenue (ttm) | 75.13M |
| Net Income (ttm) | -146.41M |
| Shares Out | 303.16M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,809,823 |
| Open | 4.000 |
| Previous Close | 4.160 |
| Day's Range | 3.960 - 4.295 |
| 52-Week Range | 1.940 - 6.515 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 8.40 (+102.17%) |
| Earnings Date | May 11, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $8.4, which is an increase of 102.17% from the latest price.
News
AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
The company has transitioned from a partnership-driven model to advancing its own pipeline, with a focus on challenging antibody targets and a strong liquidity position. Lead asset ABCL635 targets hot flashes in menopausal women, with key phase II data expected in Q3 and potential expansion into oncology-related indications.
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
A robust antibody-based drug discovery platform supports a growing pipeline, with lead asset ABCL635 in phase II targeting menopausal hot flashes and potential expansion to cancer therapy-induced symptoms. In-house manufacturing and strong financial backing enable flexibility and sustained development.
AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference
The company has evolved into a biotech with robust antibody discovery and manufacturing capabilities, advancing a pipeline led by ABCL635 for menopausal VMS, which is differentiated by safety and dosing convenience. Phase II data for ABCL635 is expected in Q3, with rapid expansion into oncology and additional assets progressing toward clinical trials.
AbCellera Biologics Earnings Call Transcript: Q4 2025
Transitioned to a clinical-stage biotech, expanded pipeline to four clinical/IND-enabling programs, and ended 2025 with $700M liquidity. Revenue rose to $75M, net loss narrowed to $146M, and key clinical readouts are expected in 2026.
AbCellera Reports Full Year 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.
AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company has transitioned to a clinical-stage model, advancing a robust pipeline led by ABCL635 for menopause symptoms, with key data readouts expected in 2025. Strong liquidity, a new GMP facility, and a focus on differentiated, high-need indications position it for late-stage clinical expansion.
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause...
AbCellera and Bruker Reach Global Settlement of Patent Litigation
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference
Transitioning to a clinical-stage biotech, the company now prioritizes internal drug development, highlighted by advanced programs in menopause and atopic dermatitis. Strong liquidity and end-to-end capabilities support a robust pipeline, with over 20 assets in development.
AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference
The company has completed its transition to developing proprietary clinical assets, with two wholly owned drugs in the clinic and a third in IND-enabling studies. ABCL635 targets a large unmet need in menopausal hot flashes, with proof-of-concept data expected in 2025. Liquidity exceeds CAD 700 million, supporting at least three years of operations.
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.
AbCellera Biologics Earnings Call Transcript: Q3 2025
Transitioned to a clinical-stage biotech with two phase I trials underway and strong liquidity of $680M. Revenue rose to $9M, but net loss widened to $57M as R&D investment increased. Confident in advancing pipeline and maintaining funding for over three years.
AbCellera Reports Q3 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The company has shifted from a partnership and royalty model to advancing its own pipeline, with two proprietary antibodies now in clinical trials and more in development. Strong execution, robust financials, and differentiated assets targeting large unmet needs position it for future growth.
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.
AbCellera to Participate at Upcoming Investor Conferences in September
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.
AbCellera Biologics Earnings Call Transcript: Q2 2025
Q2 2025 saw major clinical milestones with two programs entering phase I trials and a third advancing to IND-enabling studies. Revenue rose sharply due to a one-time licensing fee, while liquidity remains strong at $750 million. Initial clinical data for lead assets is expected in mid-2026.